| Literature DB >> 32063968 |
Sumbal Nosheen1, Nadeem Irfan Bukhari2, Hasan Ejaz3, Nasir Abbas4.
Abstract
OBJECTIVE: To gauge the recent breadth of MDR E. coli along with antibiogram of carbapenemase producing (CP) E. coli among children from an institute which receives patients from all over Punjab.Entities:
Keywords: Antibiotic resistance; Carbapenemase producers; Escherichia coli; Multi-drug resistance
Year: 2020 PMID: 32063968 PMCID: PMC6994894 DOI: 10.12669/pjms.36.2.928
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 1.088
Demographic data of patients infected with CP E. coli infections (n=113).
| Specimen | Frequency (n) | Percentage (%) |
|---|---|---|
| Blood | 42 | 37.20% |
| Ear Swab Tip | 3 | 2.70% |
| CVP Tip | 4 | 3.50% |
| PD Catheter | 4 | 3.50% |
| Pus | 6 | 5.30% |
| Urine | 40 | 35.40% |
| Tracheal secretion | 2 | 1.80% |
| CSF | 9 | 8% |
| ETT | 1 | 0.90% |
| Wound Swab | 2 | 1.80% |
| Neonatal Unit | 22.0 | 19.5% |
| Development Ward | 2.0 | 1.8% |
| Surgery Ward | 4.0 | 3.5% |
| All Intensive Care Units (ICUs) | 14.0 | 12.4% |
| Medical Emergency | 2.0 | 1.8% |
| Haematology/Oncology Unit | 15.0 | 13.3% |
| Cardiology Ward | 1.0 | 0.9% |
| Outdoor Patients (OPD) | 7.0 | 6.2% |
| Urology Ward | 3.0 | 2.7% |
| General Medical Unit-I | 3.0 | 2.7% |
| General Medical Unit-II | 11.0 | 9.7% |
| General Medical Unit-III | 4.0 | 3.5% |
| General Medical Unit-IV | 3.0 | 2.7% |
| Nephrology Ward | 15.0 | 13.3% |
| Gastroenterology Ward | 3.0 | 2.7% |
| Neurology ward | 1.0 | 0.9% |
| Neuro-Surgery ward | 3.0 | 2.7% |
| Female | 56 | 49.6% |
| Male | 57 | 50.4% |
| Discharge | 73 | 65% |
| Death | 17 | 15% |
| LAMA (left against medical advice) | 23 | 20% |
Antibiogram of carbapenemase producing E. coli (n=113).
| Antibiotics | Resistant | Sensitive | Intermediate | |||
|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | |
| Cefoxitin | 95 | 84.1 | 12 | 10.6 | 6 | 5.3 |
| Cefuroxime | 109 | 96.5 | 4 | 3.5 | 0 | 0.0 |
| Cefixime | 110 | 97.3 | 3 | 2.7 | 0 | 0.0 |
| Ceftazidime | 113 | 100.0 | 0 | 0.0 | 0 | 0.0 |
| Ceftriaxone | 111 | 98.2 | 2 | 1.8 | 0 | 0.0 |
| Cefotaxime | 113 | 100.0 | 0 | 0.0 | 0 | 0.0 |
| Cefepime | 104 | 92.0 | 5 | 4.4 | 4 | 3.5 |
| Amikacin | 96 | 85.0 | 17 | 15.0 | 0 | 0.0 |
| Gentamycin | 108 | 95.6 | 5 | 4.4 | 0 | 0.0 |
| Tobramycin | 110 | 97.3 | 3 | 2.7 | 0 | 0.0 |
| Colistin | 89 | 78.8 | 18 | 15.9 | 6 | 5.3 |
| Nalidixic acid | 108 | 95.6 | 5 | 4.4 | 0 | 0.0 |
| Levofloxacin | 108 | 95.6 | 5 | 4.4 | 0 | 0.0 |
| Moxifloxacin | 112 | 99.1 | 0 | 0.0 | 1 | 0.9 |
| Ciprofloxacin | 106 | 93.8 | 5 | 4.4 | 2 | 1.8 |
| Norfloxacin | 102 | 90.3 | 11 | 9.7 | 0 | 0.0 |
| Aztreonam | 107 | 94.7 | 6 | 5.3 | 0 | 0.0 |
| Nitrofurantoin | 92 | 81.4 | 19 | 16.8 | 2 | 1.8 |
| Imipenem | 105 | 92.9 | 4 | 3.5 | 4 | 3.5 |
| Meropenem | 103 | 91.2 | 5 | 4.4 | 5 | 4.4 |
| Fosfomycin | 101 | 89.4 | 12 | 10.6 | 0 | 0.0 |
| Pipemidic acid | 112 | 99.1 | 1 | 0.9 | 0 | 0.0 |
| Co-amoxiclav | 109 | 96.5 | 4 | 3.5 | 0 | 0.0 |
| Piperacillin-tazobactam | 105 | 92.9 | 2 | 1.8 | 6 | 5.3 |
| Co-trimoxazole | 110 | 97.3 | 3 | 2.7 | 0 | 0.0 |
| Cefoperazone-sulbactam | 102 | 90.3 | 4 | 3.5 | 7 | 6.2 |
p<0.05 using Friedman test used to see the difference in the effects of antibiotics